Life Sciences Archive » May, 2011

Life Sciences - May, 2011

173 articles

• FDA Probes Yaz, Others Over Blood Clot Risks
• Orthovita Shareholders Sue Over $316M Stryker Deal
• WHO Says Cellphone Radiation May Cause Cancer
• Pfizer Ends Patent War Over Generic Neurontin
• High Court Won't Hear Novartis Appeal Of Zometa Suit
• Following Follow-On Biologics Legislation
• Katten Nabs Dewey IP Pro In NY
• Abbott Sues Boehringer Unit Over Generic Zemplar
• Galderma, Supernus Sue Impax Over Rosacea Treatment
• Somaxon Slaps Par With 2nd Suit Over Generic Silenor
• Steptoe Adds Winston Partner To Chicago IP Team
• ARB Ruling Offers Broad View Of SOX Protections
• Exporter Admits To $1.3M FDA Fraud
• Case Study: Cynosure V. St. Paul Fire & Marine
• The HEAT Is On, Chicago: Practical Tips To Prepare
• SG Sides Against Novo In Dispute Over Generics
• Judge Refuses To Toss Botox Marketing Class Action
• Ex-Nasdaq Exec Pleads Guilty To Insider Trading
• Amylin Wins Restraining Order On Lilly Drug Sales
• Jury Sides With Novartis In Widow's Bone Drug Suit
• GSK, Pfizer, Others Targeted In DNA Patent Suit
• Fed. Circ. Tightens Inequitable Conduct Standards
• Sanofi Paid Doctors To Help Delay Lovenox Generic: Sens.
• Medtronic's Infuse Tied To Male Infertility Risks
• 34 Women Sue AstraZeneca Over Nexium Bone Risks
• Plaintiffs, Claims Added To $100M Bayer Sex Bias Suit
• AstraZeneca Adds Intellipharmaceutics To Seroquel Row
• Watson Expands Generics Biz With $562M Specifar Buy
• FDA Issues Class 1 Recall Of Beckman Blood Analyzer
• Adviser Gets 2 Years For Trading On Ex-UBS Banker's Tips
• Apotex Infringed Alcon's Eye Drop Patent: Judge
• FTC Urges 3rd Circ. To Reverse Pay-For-Delay Ruling
• Fed. Circ. Revives Competition Claims In Latisse Suit
• Defining The Essential Health Benefits Package
• Applied Medical Hits Covidien With Seal Patent Suit
• After Failed Cephalon Bid, Valeant Buys Sanitas For $443M
• Philips Recalls Infant, Neonatal CO2 Devices
• JPML Consolidates Depuy Hip Implant Suits in Texas
• Judicial Panel Consolidates Fosamax Femur Fracture Suits
• JPML Won't Separate La. Avandia Suit From MDL
• Pa. Jury Slaps J&J Unit With $10M Motrin Verdict
• J&J Buys Russian Cold Drug Brands For $260M
• The Complexities Of Bifurcated Markman Proceedings
• High Court Preemption Ruling Would Hit Branded Cos. Hard
• XenoPort Investors' Horizant Suit Tossed For Now
• 4th Circ. Returns W.Va. Pharmacy Suit To State Court
• Cephalon Granted TRO In Amrix Patent MDL
• Mylan Settles Kentucky Drug-Pricing Suit For $6.5M
• Pfizer Resubmits Thousands Of Adverse Chantix Reports
• Allergan Hits Lupin With 2nd Eye Drop Patent Suit
• Novartis Seeks To Nix Expert Testimony In Bone Drug MDL
• 9th Circ. Nixes Pharmacies' Pfizer-Wyeth Merger Suit
• FBI Seeks Unabomber DNA Over 1982 Tylenol Deaths
• Genentech Sues Apotex Over Generic Valcyte
• Insurers Seek To Avoid Covering Skin Care Co. Fights
• FDA Urged To Pull Eisai's High-Dose Aricept
• Exela Didn't Infringe Alphagan IP: Fed. Circ.
• Global 20: Clifford Chance
• Abbott Wins IP Validity Ruling In Niaspan Suit
• CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
• Q&A With Morrison & Foerster's James Huston
• Takeda Goes Global With $13.7B Nycomed Deal
• WilmerHale Reps Thermo Fisher In $3.5B Phadia Buy
• Judge Stays Case Over Point Blank Deregistration Plan
• FDA Pulls Avandia From US Pharmacies
• Firms, Experts Allowed To Stay In AndroGel MDL
• Nycomed, Glenmark Settle Feud Over Cutivate
• Revise Pain-Med Dosing Tips For Children: FDA Panels
• CVS, Rite Aid Strike Deal In OxyContin MDL
• Q&A With Fish & Richardson's John Adkisson
• Neurontin Judge Won't Certify 3rd-Party Bipolar Class
• FDA Warns Shire About Vyvanse Marketing
• Global 20: Baker & McKenzie
• NJ Class Suit Targets Bayer Probiotics Products
• Ropes & Gray Reps InVentiv In PharmaNet Purchase
• Schiff Nutrition Sued Over Dietary Supplement Claims
• Cravath Reps Rosetta In $575M Sale To Publicis
• Genzyme Sues Allergan Over Juvederm Gel IP
• Supreme Court Won't Hear Howmedica Polymer IP Appeal
• Global 20: DLA Piper
• Day Trader Admits To Profiting From BrunswickTips
• Ga. High Court Favors Vaccine Makers In Defect Case
• Amylin Sues Lilly Over Byetta Sales Plans
• Recent Developments In Acquisition Finance
• Lupin Steps Up Fight With Mylan Over Generic Antara
• Fed. Circ. Upholds Rejection Of 2 Endo Opana Patents
• Lloyd's Doesn't Owe Bristol-Myers $11M For Theft: Suit
• Pfizer Expects To Pay $772M To End Hormone Drug Suits
• 2 Get $3M Fine In Merrill, Goldman Insider Trading Suit
• Cephalon's Amrix IP Invalid, Infringed: Judge
• 1st Circ. Says Insurer Isn't Liable In Cynosure Suit
• I'm Glad High Court Nixed Cipro Cert Bid: FTC Commish
• Kinetic Unit Warned Over Breast Implant Marketing
• US Seeks $1B From J&J Over Risperdal Marketing
• Advanced Generic Reloads In Antitrust Suit V. Drug Cos.
• Disgorgement: A Cure Worse Than The Disease?
• Playboy, Drake Ink Deal On 'Best I Ever Had' Dispute
• Possible Outcomes Of Stanford V. Roche
• GSK Beats ERISA Class Action Over Stock Price Drop
• 8th Circ. Won't Rehear KV Drug Recall Action
• Remedi Sues Zurich Over Medicare Suit Coverage
• Boston Scientific Wins $19.5M In Stent Patent Case
• Cephalon Drops Nuvigil Patent Suit Against Teva
• Judge Snips DaVita Kickback Claims In FCA Suit
• FDA Asked To Probe 3M's MRSA Clinical Test Conduct
• Morgan Lewis Adds 2 McKenna Gov't Contract Pros
• Q&A With Sidley Austin's Thomas Hanrahan
• J&J Recalls HIV Drug Over Odor-Causing Chemical
• J&J Unit Sets Funds Aside For Risperdal Settlement
• Sanofi, Generics Failed To Report Ambien IP Deals: FTC
• FDA Orders 21 Hip Reserve Makers To Study Defects
• Somaxon Sues Actavis Over Generic Silenor
• Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
• High-Ranking DOJ Fraud Cop Heads To Mintz Levin
• Is SCOTUS Taking The Right Securities Cases?
• Wilson Sonsini Lures IP Litigator From Katten Muchin
• GSK Atty Acquitted On All Counts In Obstruction Case
• Forest Labs Subpoenaed Over Hypertension Meds
• US Can't Prove Wellbutrin Statements False: GSK Atty
• Health Care Industry Feels The HEAT
• Reissue Ruling A Boost To Patentees In Validity Fights
• Lilly Claims Zydus Broke Deal In Strattera Row
• Cleary Gottlieb Reps Alkermes In $960M Elan Unit Buy
• Canada High Court To Hear Teva's Viagra Patent Appeal
• 5 Prosecutors White Collar Attorneys Should Know
• Ivera Sues Excelsior Over Medical Valve Patent
• Synthes Investor Blasts $21B J&J Deal In Suit
• FTC Clears $338M Baxter-Prism Pharmaceuticals Deal
• Merck Unit Sues Sandoz Over Generic Noxafil
• Morgan Lewis Criminal Defense Pro Jumps To Dickstein
• Crowell Picks Up Hatch-Waxman Experts From Frommer
• J&J Units Again Sue To Block Impax's Generic Concerta
• Inspire Shareholders Try To Block $430M Merck Takeover
• Bayer Targets Lilly In False Ad Suit Over Pet Drugs
• Yaz Consumers Fail To Win Class Cert. In MDL Case
• Conn. AG, CVS Settle Expired Products Suit
• Medtronic Loses Bid To Take Lenox Suit To Arbitration
• Doctors Were Chastised For Wellbutrin Claims: GSK Exec
• 2nd Circ. Upholds $4M Fine In Insider Trading Suit
• Flamel Takes Lupin To Court Over Generic Coreg
• Off-Label Use OK When Not Promoted, GSK Exec Says
• Former Cigna Atty Returns To Take On GC Role
• Merck Units To Pay $44M In Rebif Whistleblower Suit
• Jazz Hits Roxane With Patent Suit Over Xyrem
• Barnes & Thornburg Lands Ex-Faegre & Benson Co-Chair
• Prescriptions For FCPA Pain
• Investor Tries To Stop LabCorp's $85M Orchid Buyout
• Actelion Vows To Appeal Jury Verdict In Asahi Fight
• GSK Scripted Response For Wellbutrin Probe, Atty Says
• Investors Sue J&J Board Over $78M In Settlements
• Pay-For-Delay Deals Hit 7-Year High In 2010: FTC
• Takeda Sues Mylan Over Prevacid Patents
• Hatch Pushes To Repeal State Medicaid Mandate
• Blank Rome Snags Ex-Cozen Life Sciences Chair
• Wyeth Improperly Delayed Generic Effexor: Suit
• Senate Probes Medtronic Decision To Nix GPO Contracts
• US Regulators Clamp Down On Illegal STD Drugs
• Abbott Slaps Teva With Suit Over Generic AndroGel
• Pfizer, Eon Settle Neurontin Patent Claims
• Taro Sues Suven To Block Generic Lice Treatment
• Case Study: Wolfe V. McNeil-PPC
• Rembrandt Sets Sights On CooperVision Over Lens IP
• FDA Gets Mylan Suit Over Generic Lipitor Tossed
• Impax Gets Amgen Vet As New GC
• Ex-Atty Makes Plea For Leniency In Galleon Spinoff
• AstraZeneca Ends Seroquel Case Against Biovail
• Santarus Defends Zegerid Patents In Fed. Circ.
• FTC Clears Pfizer's $2.4B Capsugel Sale To KKR
• Grifols, FTC Ink Deal To Allow $3.4B Talecris Tie-Up
• Jones Day Lures M&A Pro From Edwards Angell
• Medicines Co. Sues Dr. Reddy's Over Generic Angiomax
• Killing The Golden Goose
• Teva Tops Valeant With $6.8B Cephalon Buy